Study of Sacituzumab Govitecan in Patients With Solid Tumor
- Registration Number
- NCT05119907
- Lead Sponsor
- Gilead Sciences
- Brief Summary
The goal of this study is to learn more about the study drug, sacituzumab govitecan-hziy, in participants with solid tumor.
- Detailed Description
Only Cohort C: Cervical Cancer (CC) is enrolling at this time.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 300
-
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.
-
Histologically or cytologically-documented, incurable locally advanced or metastatic solid tumor of one of the following types:
- Cohort A: oesophageal squamous-cell carcinoma that was refractory or intolerant to fluoropyrimidine-based, platinum-based, and taxane-based chemotherapy.
- Cohort B: gastric adenocarcinoma that was refractory or intolerant to fluoropyrimidine-based, platinum-based, and taxane-based chemotherapy.
- Cohort C: cervical cancer that was refractory or intolerant to platinum-based and taxane-based chemotherapy.
- Cohort D: biliary tract cancer, including intrahepatic cholangiocarcinoma (IHCC), extrahepatic cholangiocarcinoma (EHCC), and gallbladder cancer (GBC), with exception of ampullary carcinoma, progressed during or after first line platinum-based or fluoropyrimidine-based chemotherapy.
- Cohort E: lung adenocarcinoma with activating genomic alterations (EGFR/ ALK/ ROS1/ BRAF/ MET/ RET) that was refractory or intolerant to targeted tyrosine kinase inhibitors (TKIs) and had not received platinum-based chemotherapy for unresectable local advanced or metastatic disease, and no suitable or willing to receive platinum-based chemotherapy.
-
Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) in accordance with RECIST v 1.1, bone-only disease is not measurable and is not permitted.
-
Availability of archival tumor tissue or newly acquired biopsy (unstaining tumor slides, recommended from metastasis sites).
-
Adequate bone marrow, hepatic and renal function.
-
Recovered from all prior treatment-related toxicities to Grade 1 or less by NCI-CTCAE v 5.0 (except alopecia or peripheral neuropathy that may be Grade 2 or less).
-
Individuals must have completed all prior cancer treatments at least 2 weeks prior to the first dose including chemotherapy , radiotherapy and major surgery. Prior antibody treatment for cancer must have been completed at least 3 weeks prior to the first dose.
-
Individuals must have at least a 3-month life expectancy.
Key
- Previous treatment with topoisomerase I inhibitors as a free form or as other formulations.
- Previous treatment with Trop-2 targeted therapy.
- Individuals with a history of or current central nervous system (CNS) metastases.
- Known additional malignancy within 3 years prior to enrollment with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or curatively resected in situ cancers.
- Individuals known to be human immunodeficiency virus positive.
- Individuals with active hepatitis B virus (HBV), or hepatitis C virus (HCV) infection. Hepatitis B core antibody (HBcAb) testing is required and if positive, then HBV DNA testing will be performed and if positive the individual will be excluded.
- Known history of unstable angina, myocardial infarction (MI), or chronic heart failure present within 6 months of first dose or clinically significant cardiac arrhythmia (other than stable atrial fibrillation) requiring anti-arrhythmia therapy or left ventricular ejection fraction < 50%.
- Known history of clinically significant active chronic obstructive pulmonary disease, or other moderate-to-severe chronic respiratory illness present within 6 months of the first dose.
- Infection requiring systematic antibiotic use within 1 week of the first dose.
- Individuals with active chronic inflammatory bowel disease (ulcerative colitis, Crohn disease) and individuals with a history of bowel obstruction or gastrointestinal (GI) perforation.
- High dose systemic corticosteroids within 2 weeks prior to the first dose (however, low dose corticosteroids ≤ 10 mg prednisone or equivalent daily are permitted provided the dose is stable for 4 weeks).
- Individuals who have received a live vaccine within 30 days of first dose.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Cohort A: Esophageal Squamous Cell Carcinoma (ESCC) Sacituzumab Govitecan-hziy Participants will receive Sacituzumab Govitecan-hziy (SG) 8 or 10 mg/kg on Days 1 and 8 of a 21-day cycle. Participants will continue treatment until disease progression or intolerable toxicity or consent withdrawal for any reason. Cohort B: Gastric or Gastroesophageal Junction Adenocarcinoma (G/GEJC) Sacituzumab Govitecan-hziy Participants will receive SG 8 or 10 mg/kg on Days 1 and 8 of a 21-day cycle. Participants will continue treatment until disease progression or intolerable toxicity or consent withdrawal for any reason. Cohort C: Cervical Cancer (CC) Sacituzumab Govitecan-hziy Participants will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle. Participants will continue treatment until disease progression or intolerable toxicity or consent withdrawal for any reason. Cohort D: Biliary Tract Cancer (BTC) Sacituzumab Govitecan-hziy Participants will receive SG 8 or 10 mg/kg on Days 1 and 8 of a 21-day cycle. Participants will continue treatment until disease progression or intolerable toxicity or consent withdrawal for any reason. Cohort E: Lung Adenocarcinoma (LAC) Sacituzumab Govitecan-hziy Participants will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle. Participants will continue treatment until disease progression or intolerable toxicity or consent withdrawal for any reason.
- Primary Outcome Measures
Name Time Method Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v 1.1) By Investigator Assessment Up to 4 years ORR is defined as the proportion of participants who achieve a complete response (CR) or partial response (PR).
- Secondary Outcome Measures
Name Time Method Duration of Response (DOR) Up to 4 years DOR is defined as the time from the first documentation of CR or PR to the earlier of the first documentation of definitive progressive disease (PD) or death from any cause (whichever comes first).
Disease Control Rate (DCR) Up to 4 years DCR is defined as the proportion of participants who achieve CR, PR, or stable disease (SD).
Progression-free Survival (PFS) Up to 4 years PFS is defined as the time from the first dose of sacituzumab govitecan-hziy (SG) until the date of objective PD, or death (whichever comes first).
Overall Survival (OS) Up to 4 years OS is defined as the time from the first dose of SG until death due to any cause.
Percentage of Participants Experiencing Adverse Events (AEs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 First dose date up to 4 years plus 30 days Percentage of Participants Experiencing Serious Adverse Events (SAEs) According to NCI CTCAE Version 5.0 First dose date up to 4 years plus 30 days Pharmacokinetic (PK) Parameter: Cmax of Sacituzumab Govitecan-hziy and Free SN-38 Up to 4 years Cmax is defined as the maximum observed concentration of drug.
PK Parameter: Tmax of Sacituzumab Govitecan-hziy and Free SN-38 Up to 4 years Tmax is defined as the time (observed time point) of Cmax.
PK Parameter: Ctrough of Sacituzumab Govitecan-hziy and Free SN-38 Up to 4 years Ctrough is defined as the concentration of drug at the end of the dosing interval.
Percentage of Participants Who Developed Anti-Drug Antibodies (ADAs) Against SG Up to 4 years
Trial Locations
- Locations (13)
Anhui Provincial Hospital
🇨🇳Hefei, China
Chinese Academy of Medical Sciences Cancer Hospital
🇨🇳Beijing, China
Beijing Obstetrics and Gynecology Hospital, Capital Medical University
🇨🇳Beijing, China
Beijing Cancer Hospital
🇨🇳Beijing, China
The First Hospital of Jilin University
🇨🇳Changchun, China
The First Affiliated Hospital, Zhejiang University School of Medicine
🇨🇳Hangzhou, China
The Sixth Affiliated Hospital, Sun Yat-Sen University
🇨🇳Guangzhou, China
Zhejiang Cancer Hospital
🇨🇳Hangzhou, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
🇨🇳Wuhan, China
Jiangsu Province Hospital
🇨🇳Nanjing, China
Henan Cancer Hospital
🇨🇳Zhengzhou, China
Harbin Medical University Cancer Hospital
🇨🇳Harbin, China
Fujian Cancer Hospital
🇨🇳Fuzhou, China